Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
ConditionFibrillary Glomerulonephritis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
Eligibility criteria
Qualifiers
≥18 years of age
Biopsy proven fibrillary glomerulonephritis
Proteinuria > 1.0 g/24hrs prior to initiation of immunosuppressive therapy
eGFR ≥ 20 ml/min/BSA
Disqualifiers
Secondary FGN (due to monoclonal gammopathy, autoimmune disease or malignancy)
Presence of a secondary pathology on biopsy (e.g. diabetic nephropathy)
Hepatitis B, C or HIV positive
Pregnant or breast-feeding
Trial design
Treatments tested in this trial
- Obinutuzumab
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov